Objectives: Emerging evidences indicated the importance of long non-coding RNAs (lncRNAs) in the tumorigenesis and deterioration of malignant tumours. To our knowledge, the study about lncRNAs in papillary thyroid carcinoma (PTC) is still inadequate. ABHD11-AS1 was highly expressed in the PTC samples of The Cancer Genome Atlas database. This study focused on the biological function and mechanism of lncRNA ABHD11-AS1 in PTC. 
| INTRODUC TI ON
Thyroid cancer is a kind of commonest endocrine system malignant tumours. The mortality of patients with thyroid cancer is rapidly increasing over the past decades. 1 
Papillary thyroid carcinoma (PTC)
is the commonest subtype of thyroid cancer. 2 There are some risk factors for PTC, such as ionizing radiation exposure, thyroid nodular disease and the family history. 3 However, the specific mechanism underlying PTC is widely elusive. Therefore, investigating the potential molecular mechanism involved in PTC progression is very essential to find novel biomarkers or therapeutic targets for PTC.
As a subtype of non-coding RNAs (ncRNAs), long non-coding RNAs (lncRNAs) are originally defined as transcriptional noise. 4, 5 Importantly, the dysregulation of lncRNAs can affect the progression of various human diseases, including cancers. The most significant function of abnormally expressed lncRNAs is to regulate cellular processes in human cancers and determine the outcomes for cancer patients. 6, 7 Epigenetic regulation is a major reason for aberrant expression of lncRNAs. For instance, H3K27 acetylation-mediated activation induces high expression of lncRNA CCAT1 in oesophageal squamous cell carcinoma, 8 whereas the downregulation of p53-induced lncRNA TP53TG1 is caused by the high methylation of its gene promoter. 9 Additionally, upregulation of lncRNAs induced by its upstream transcription factor can promote tumour progression in various human cancers. [10] [11] [12] [13] The dysregulation of lncRNAs has been identified as an oncogenic factor for the tumour progression. [14] [15] [16] [17] Therefore, it is crucial to investigate the mechanism of lncRNAs in human cancers.
Based on the data of The Cancer Genome Atlas (TCGA) database, ABHD11-AS1 was significantly highly expressed in PTC samples.
qRT-PCR exanimation further detects the expression of ABHD11-AS1 in 82 PTC tissues. Kaplan-Meier method was to identify the effect of ABHD11-AS1 expression on the prognosis of PTC patients.
The oncogenic role of ABHD11-AS1 in PTC was identified by performing loss-of-function assays. Therefore, we further detected the molecular mechanism of ABHD11-AS1 in PTC progression. As a transcription activator of lncRNAs, STAT3 has been reported in various human cancers. 18, 19 In this study, STAT3 was demonstrated to be able to activate ABHD11-AS1 transcription. Furthermore, we applied microarray analysis and KEGG analysis to find the molecular mechanism involved in ABHD11-AS1-mediated biological behaviours of PTC cells. Previous reports showed that STAT3 can bind to miRNAs by competing with lncRNAs. [20] [21] [22] [23] Therefore, we F I G U R E 1 Upregulation of lncRNA ABHD11-AS1 predicted unfavourable prognosis for patients with PTC. A, The expression of lncRNA ABHD11-AS1 in the thyroid cancer tissues of TCGA database was detected. B, The expression of ABHD11-AS1 was measured in 82 pairs of PTC tissues and adjacent non-tumour tissues. C,D, The conspicuous fold change of ABHD11-AS1 in paired tumour tissues and non-malignant tissues was further analysed and illustrated. E, The importance of ABHD11-AS1 expression for the prognosis of PTC patients was analysed by Kaplan-Meier analysis. *P < 0.05, **P < 0.01. PTC: papillary thyroid carcinoma hypothesized that ABHD11-AS1 might positively regulate STAT3 by competitively binding to a miRNA. Bioinformatics analysis and mechanism experiments were conducted to demonstrate our hypothesis.
Finally, rescue assays demonstrated the function of ABHD11-AS1-miR-1301-3p-STAT3 axis in PTC progression.
| MATERIAL S AND ME THODS

| Tissue samples
Paired tissues (tumour and non-tumour) were obtained from 82 PTC patients who received surgery at Navy General Hospital. None of these patients received chemotherapy or radiotherapy before this study.
Patients with other tumours or tumour history were excluded from this study. Total samples were dissected immediately, placed on ice, snapfrozen with liquid nitrogen and stored at −80°C for later use. This study had been approved by the ethics committee of Navy General Hospital.
All patients have signed the informed consents before the study.
| Cell culture
The BCPAP (PTC cell line) was purchased from DSMZ (Braunschweig, Germany). Nthy-ori 3-1 (the normal cell line) and K1 (PTC cell line)
were obtained from the European Collection of Authenticated Cell Culture (ECACC, Salisbury, UK). BHP5-16 and BHP2-7 (PTC cell lines)
were obtained from the American Type Culture Collection (ATCC;
Manassas, VA, USA). RPMI 1640 (Invitrogen, Carlsbad, CA, USA) with 10% foetal bovine serum (Gibco BRL, Rockville, MD, USA), 100 mg/mL streptomycin (Invitrogen) as well as 100 U/mL penicillin was used for cell culture. Cell culture was performed at 37°C in a humidified atmosphere with 5% CO 2 .
| Detection of mycoplasma contamination
The mycoplasma contamination of cells was detected with Myco-
PCR-Mix mycophenolate mycoplasma detection kit (Qiao Xinzhou
Bioengineering Co. Ltd., Shanghai, China). The experimental results are shown in Figure S1 .
| Cell transfection
shRNA targeted to ABHD11-AS1 (sh-ABHD11-AS1) and corresponding negative control (sh-NC) were used for ABHD11-AS1
knockdown. The shRNA sequences were shown as follows: sh-ABHD11-AS1: GAGGGACCTCCAGGGACGAGAGGACAGG, sh-NC:
CGATTGTTCTTCTTTCTAGTTAAGAGAA. miR-1301-3p was overexpressed or silenced with miR-1301-3p mimics or miR-1301-3p inhibitors. To overexpress STAT3, the whole sequence of STAT3 was subcloned into pcDNA3.1 vector. All these plasmids and expression for further analysis at 48 hours after transfection. Notes. Low/high by the sample median. Pearson chi-square test. PTC: papillary thyroid carcinoma. *P < 0.05, **P < 0.01 was considered to be statistically significant. 
| RNA extraction and qRT-PCR
| MTT
| Colony formation assay
Following transfection for 72 hours, total cells were trypsinized (Solarbio, Beijing, China), plated into six-well plates at 200 cells each well and cultured for 21 days using RPMI 1640 (Invitrogen) containing 10% foetal bovine serum (Gibco) under routine conditions.
Medium was replaced when needed. After that, colonies were fixed by methanol and stained by 0.5% crystal violet (Sigma). Visible colonies were counted manually. 
| Flow cytometry analysis of apoptosis
| Caspase-3 activity assay
The apoptosis condition was examined by using caspase-3 activity kit (Beyotime Institute of Biotechnology, Nantong, China). In short, after cell transfection, 2 × 10 6 cells seeded in six-well plates were lysed in lysis buffer (as provided in the kit) for 15 minutes at 4°C, F I G U R E 2 ABHD11-AS1 knockdown suppressed cell proliferation and induced cell apoptosis in PTC. A, The expression level of ABHD11-AS1 was examined in one normal cell line (Nthy-ori 3-1) and four PTC cell lines (BHP5-16, BCPAP, K1 and BHP2-7). B, The shRNA specifically targeted to ABHD11-AS1 (sh-ABHD11-AS1) and negative control shRNA (sh-NC) were transfected into BCPAP and K1 cells. The interference efficiency was validated by using qRT-PCR. C,D, Cell proliferation was observed with MTT and colony formation assay after sh-ABHD11-AS1 transfection. E,F, Flow cytometry analysis and caspase-3 activity detection were performed to measure the apoptotic rate of PTC cells transfected with sh-ABHD11-AS1. *P < 0.05, **P < 0.01. PTC: papillary thyroid carcinoma 
| Cell migration assay
Cell migration was examined with transwell assays. In short, indi- and quantified through counting 10 random fields. Hospital. The nude mice used in this study are healthy. All these mice are with same age and similar weight. Four weeks later, the nude mice were sacrificed. Tumour volume and weight were measured and calculated every 7 days by using a formula (0.5 × length × width 2 ). This study was approved by the Committee Ethics of Animal Center of the Qilu Hospital of Shandong University.
| Tumour xenograft model
| In vivo tumour metastasis assay
All animal studies had acquired the approval of the Animal Experimental Committee of Qilu Hospital of Shandong University.
The BALB/c nude mice (male, 4-5 weeks old) were obtained from the Experimental Animal Center of Navy General Hospital. The nude mice used in this study are healthy. All these mice are with same age and similar weight. To conduct in vivo metastasis assays, 1 × 10 7 cells were implanted subcutaneously into the right hind flank regions of the two different groups (n = 3 each group). Tumour growth was recorded with the digital callipers every 7 days. Sixty days later, all mice were sacrificed so as to observe the lung and liver metastasis.
Finally, the metastatic tissues were photographed and detected by H&E staining under a microscope.
| Immunofluorescence
Cells were grown on glass coverslips and fixed with 4% formaldehyde for 10 minutes followed with the permeabilization in 0.5% Triton X-100 at room temperature for 15 minutes. 
| Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization Kit (GenePharma, Shanghai, China) was used to perform FISH assay. ABHD11-AS1 was labelled with the FAM probe, and nucleus was stained with DAPI. U6 was used as the control of nuclear fraction, while 18S rRNA was used as the control of cytoplasmic fraction.
| Luciferase reporter assay
The different fragment sequences predicted by JASPAR were synthesized and inserted into the pGL3-basic vector (OMEGA Engineering Inc., Norwalk, CT, USA). Subsequently, the constructed vectors were transfected into BCPAP and K1 cells along with STAT3 expression vector or NC. Forty-eight hours later, the luciferase activity was evaluated with a Dual Luciferase Assay Kit (OMEGA Engineering Inc).
| ChIP
ChIP was conducted by the use of the ChIP assay kit following 
| RIP assay
The MagnaRIP RNA-Binding Protein Immunoprecipitation Kit 
| RNA pull-down assay
| Western blotting
RIPA lysis buffer (Beyotime Biotechnology) containing protease inhibitors (Roche) was applied to extract the proteins. Q uantification of proteins was carried out applying the BCA™ Protein Assay Kit (Pierce, Appleton, WI, USA). After that, proteins (30 μg/sample)
were loaded and electrophoresed with 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, followed by the transfer to the polyvinylidene difluoride membranes. The primary antibody used in this study was as below: PI3K (ab86714), p-P13K (ab191606), AKT (ab81283), p-AKT (ab38449), mTOR (ab32028), p-mTOR (ab109268), E-cadherin (ab76055), β-catenin (ab32572),
N-cadherin (ab18203), vimentin (ab92547) and GAPDH (ab8245).
The antibodies were prepared in 5% blocking buffer with a dilu- peroxidase at room temperature for 2 hours. The antibodies used in this study were purchased from Abcam (Cambridge, MA, USA).
Immobilon Western Chemiluminescent HRP Substrate (200 μL;
Millipore) was used to cover the surface of membrane. Finally, the signals were captured, and the concentration of the bands was quantified using Image Lab™ software (Bio-Rad Laboratories, Hercules, CA, USA).
| Statistical analysis
Data of all experiments were presented as mean ± standard deviation (SD). All experimental procedures were repeated at least three times. Statistical analysis was conducted using GraphPad Prism 6.0 statistical software (GraphPad Software Inc, La Jolla,
CA, USA). Student's t test for two groups or Bonferroni test
for more than two groups was used to analyse the differences.
Kaplan-Meier method was used to analyse the overall survival of PTC patients with high or low expression of ABHD11-AS1.
Expression association was analysed with Spearman's correlation analysis. P value <0.05 implied a statistically significant result.
| RE SULTS
| Upregulation of lncRNA ABHD11-AS1 predicted unfavourable prognosis for patients with PTC
Based on the data of TCGA database, we found that lncRNA ABHD11-AS1 was significantly upregulated in PTC samples ( Figure 1A ). Next, we examined the level of ABHD11-AS1 in 82 pairs of PTC tissues and non-malignant tissues. Unsurprisingly, ABHD11-AS1 was expressed higher in PCT tissues ( Figure 1B) . The conspicuous fold change of lncRNA ABHD11-AS1 in paired tumour tissues and non-malignant tissues was further analysed and illustrated ( Figure 1C,D) . The expression level of ABHD11 presented no significant expression difference between PTC tissue samples and normal tissue samples ( Figure S2A,B) . Moreover, the expression of ABHD11 was significantly changed by ABHD11-AS1 knockdown ( Figure S2C ). Moreover, we found three transcripts of ABHD11 with specific sequence ( Figure S2D) . Then, the expression of these three transcripts was decreased by ABHD11-AS1 knockdown ( Figure S2E ). Furthermore, the activity of ABHD11-AS1 promoter was decreased in cells transfected with sh-ABHD11-AS1 ( Figure   S2F ). To classify 82 PTC samples, the mean value of ABHD11-AS1 expression was used as threshold. We found that the high expression of ABHD11-AS1 was closely correlated with advanced TNM stage, lymph node metastasis and tumour infiltration (Table 1) .
Subsequently, the importance of ABHD11-AS1 expression for the prognosis of PTC patients was analysed by Kaplan-Meier analysis.
PTC patients with higher expression of ABHD11-AS1 had poorer overall survival than patients with lower expression of ABHD11-AS1 ( Figure 1E ).
| ABHD11-AS1 knockdown suppressed cell proliferation and induced cell apoptosis in PTC
To 
| Knockdown of ABHD11-AS1 inhibited the migration and EMT progress of PTC cells
Here, we further detected the effect of differentially expressed ABHD11-AS1 on the migration and EMT progress of PTC cell. The migratory capability of PTC cells transfected with sh-ABHD11-AS1
was tested with transwell assay. The result obviously showed that cell migration was noticeably suppressed by ABHD11-AS1 knockdown ( Figure 3A ). Epithelial-mesenchymal transition is known as a biological process which is closely associated with cell migration.
Therefore, we further investigated the influence of sh-ABHD11-AS1
on EMT progress by detecting the protein levels of EMT markers.
Increased level of epithelial markers (E-cadherin, β-catenin) and decreased level of mesenchymal markers (N-cadherin, vimentin) indicated the reversal effect of sh-ABHD11-AS1 on EMT progress in PTC cells ( Figure 3B ). Immunofluorescence further demonstrated the reversal effect of sh-ABHD11-AS1 on EMT progress ( Figure 3C ).
| Knockdown of ABHD11-AS1 suppressed tumour growth and metastasis in vivo
To further demonstrate the effect of ABHD11-AS1 expression on PTC tumour progression, in vivo experiments were carried out.
As shown in Figure 4A 
| ABHD11-AS1 acted as a miR-1301-3p sponge
Furthermore, we investigated the downstream molecular mechanism of ABHD11-AS1 in PTC. At first, we found that ABHD11-AS1 The binding sites between ABHD11-AS1 and these five miRNAs are shown in Figure S3 . Luciferase reporter assay suggested the binding of ABHD11-AS1 to miR-1301-3p or miR-361-3p ( Figure 7C ).
Furthermore, RIP assay revealed the binding of ABHD11-AS1 to miR-1301-3p ( Figure 7D ). Next, we examined the lower expression of miR-1301-3p in PTC tissues and cell lines ( Figure 7E,F) . The negative correlation between the expression of ABHD11-AS1 and that of miR-1301-3p in PTC tissues was analysed ( Figure 7G ). 
| D ISCUSS I ON
Over the several years, gene mutation has been identified to be crucial risk factor for PTC progression. 27 However, the molecular mechanism underlying the progression of thyroid cancer is still largely unknown. Some studies have provided the evidences to show the crucial role of lncRNAs in the initiation and development of human malignant tumours, [28] [29] [30] [31] [32] including PTC. [33] [34] [35] This study aims to investigate the potential role of a certain lncRNA in PTC. At first, lncRNA ABHD11-AS1 was chosen from TCGA database due to its ectopic expression in thyroid cancer samples.
Subsequently, lncRNA ABHD11-AS1 was subjected to qRT-PCR analysis in 82 pairs of PTC tissues and corresponding non-tumour tissues. Consistently, lncRNA ABHD11-AS1 was conspicuously upregulated in PTC tissues. It is well known that dysregulation of lncRNAs is correlated with the prognosis of cancer patients.
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Here, we applied Kaplan-Meier method to analyse the prognos- 
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